ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval

Grading or assessing a response rate to particular cancer therapies is admittedly an objective task. It depends on the type of cancer, the line of treatment, the dose, the side effects, and on and on. But when you near 90%, you tend to turn heads no matter the context.